Sam Gandy

Samuel E. Gandy is a neurologist, cell biologist, Alzheimer's Disease (AD) researcher and expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Altzhimers. His team discovered the first drugs that could lower the formation of amyloid.[1]

Sam Gandy
NationalityAmerican
Education
B.S., Charleston Southern University (Chemistry)

M.D., Ph.D., Medical University of South Carolina (Molecular Cell Biology)

Columbia University College of Physicians and Surgeons

Cornell University Medical College

The Rockefeller University
Nathan S. Kline Institute for Psychiatric Research

Years active1986-present
Medical career
ProfessionPhysician, Scientist
Institutions
Mount Sinai

South Australia Health and Medical Research Institute

Rockefeller University
New York Hospital Cornell Medical Center
ResearchAmyloid impact in Alzheimer’s disease, neurology, cell biology

As of 2020, he is Mount Sinai Professor of Alzheimer's Disease Research,[2] Professor of Neurology and Psychiatry, Icahn School of Medicine at Mount Sinai,[3] Director, Center for Cognitive Health and NFL Neurological Center Mount Sinai Hospital,[4] Visiting Principal Research Fellow, South Australia Health and Medical Research Institute in Adelaide, SA, Australia, and Chairman Emeritus of the National Medical and Scientific Advisory Council of the Alzheimer's Association. He was also Founding Director, Farber Institute for the Neurosciences.[1][5][6]

Research

Gandy has written more than 250 peer-reviewed papers,[7] chapters and reviews on this topic. He has received continuous National Institutes of Health (NIH) funding for his research on amyloid metabolism since 1986.[8] He holds four patents that can be implemented to regulate key proteins, inhibiting Alzheimer-type amyloidosis and a diagnostic method for Alzheimer disease, Huntington's disease, Parkinson's disease, dystonia ataxia, schizophrenia, epilepsy, brain tumors, brain irradiation, head trauma, and acute and chronic encephalitic and vascular disease. Gandy also studies brain imaging as a tool to confirm chronic traumatic encephalopathy (CTE) in retired athletes and war Veterans during their lifetimes.[9]

Patents

Issued patents:

Number Name Date of issue
5,385,915[10] Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation January 31, 1995
5,348,963[11] Method of screening for modulators of amyloid formation September 20, 1994
5,242,932[12] Treatment of amyloidosis associated with Alzheimer disease September 7, 1993
4,874,694[13] Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders October 17, 1989

Grants

Gandy worked on 36 research grants, 18 as principal investigator, since 1986. As of 2020, he works on nine active grants.[14][15][16][17][18]

Partial list of active grants in 2020:

Funding Source, & Number Project Title Description
NIH-NIA to NYSCF, R01 AG061894 Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late-onset sporadic Alzheimer’s disease. Develop a system based on mixing various individual iPSC-derived brain cell types or on the cultivation of organoids where all the cell types are naturally represented.
NIH-NIA, U01 AG046170 Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in AD. Identify and characterize molecular subtypes of AD with state-of-the-art network biology approaches to all existing large-scale genetic, gene expression, proteomic and functional MRI data
NIH-NIA, R01AG058469 Integrated understanding of complex viral network biology in Alzheimer’s Disease Develop and experimentally evaluate novel molecular models of microbial perturbation in AD.
NIH-NIA, RF1AG059319 Systematic Drug Repurposing Targeting Immune Activation Networks in Alzheimer’s Disease To leverage recent insights from genetic studies and drug repurposing to identify established therapies that could be repurposed to meet the great unmet need for new and effective treatments targeting immune dysfunction in AD.
NIH, R01AG057907 Integrative Network Modeling of Cognitive Resilience to Alzheimer’s Disease Systematically develop and validate molecular network models underlying cognitive resilience to AD risk.

Editorialships and boards

As of 2020, Gandy is on the editorial boards of Neurodegenerative Diseases, Journal of Neuroinflammation and The Journal of Biological Chemistry. He is an associate editor at Alzheimer’s Disease and Associated Disorders and Journal of Neuroinflammation.[19][20]

Publications

Partial list of peer-reviewed publications:

  • Gandy, Sam; DeKosky, Steven T. (29 September 2014). "[18F]-T807 tauopathy PET imaging in chronic traumatic encephalopathy". F1000Research. 3: 229. doi:10.12688/f1000research.5372.1. PMID 25469232.
  • Wilde, Elisabeth A.; Bouix, Sylvain; Tate, David F.; Lin, Alexander P.; Newsome, Mary R.; Taylor, Brian A.; Stone, James R.; Montier, James; Gandy, Samuel E.; Biekman, Brian; Shenton, Martha E.; York, Gerald (8 September 2015). "Advanced neuroimaging applied to veterans and service personnel with traumatic brain injury: state of the art and potential benefits". Brain Imaging and Behavior. 9 (3): 367–402. doi:10.1007/s11682-015-9444-y. PMC 6547383. PMID 26350144.
  • Gandy, Sam; Sano, Mary (3 November 2015). "Solanezumab—prospects for meaningful interventions in AD?". Nature Reviews Neurology. 11 (12): 669–670. doi:10.1038/nrneurol.2015.218. PMC 5959015. PMID 26526537.
  • Hunsberger, Joshua G; Rao, Mahendra; Kurtzberg, Joanne; Bulte, Jeff W M; Atala, Anthony; LaFerla, Frank M; Greely, Henry T; Sawa, Akira; Gandy, Sam; Schneider, Lon S; Doraiswamy, P Murali (February 2016). "Accelerating stem cell trials for Alzheimer's disease". The Lancet Neurology. 15 (2): 219–230. doi:10.1016/S1474-4422(15)00332-4. PMID 26704439.
  • Stoeckel, Luke E.; Arvanitakis, Zoe; Gandy, Sam; Small, Dana; Kahn, C. Ronald; Pascual-Leone, Alvaro; Pawlyk, Aaron; Sherwin, Robert; Smith, Philip (2 June 2016). "Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction". F1000Research. 5: 353. doi:10.12688/f1000research.8300.2. PMID 27303627.
  • Sano, Mary; Gandy, Sam (12 April 2016). "Sex differences in cognition". Neurology. 86 (15): 1364–1365. doi:10.1212/WNL.0000000000002573. PMID 26984948.
  • Martins, Ralph N.; Gandy, Sam (23 February 2016). "Increased dementia risk following androgen deprivation therapy?". Nature Reviews Urology. 13 (4): 188–189. doi:10.1038/nrurol.2016.34. PMID 26902342.
  • Pullman, M Y; Dickstein, D L; DeKosky, S T; Gandy, S (10 January 2017). "Antemortem biomarker support for a diagnosis of clinically probable chronic traumatic encephalopathy". Molecular Psychiatry. 22 (5): 638–639. doi:10.1038/mp.2016.236. PMID 28070125.
  • Gandy, Sam; Bartfai, Tamas; Lees, Graham V.; Sano, Mary (3 April 2017). "Midlife interventions are critical in prevention, delay, or improvement of Alzheimer's disease and vascular cognitive impairment and dementia". F1000Research. 6: 413. doi:10.12688/f1000research.11140.1. PMID 28491285.

Biography

Gandy reveived his MD and PhD at the Medical University of South Carolina.[21]

He did his postgraduate work at the Columbia University College of Physicians & Surgeons and Cornell University Medical College. Gandy completed his post-doctorate at Rockefeller University, where he was appointed assistant professor in the laboratory of Paul Greengard, 2000 Laureate of the Nobel Prize in Physiology or Medicine.[1][19]

Gandy was appointed associate professor of neurology and neurosciences at Cornell University Medical College in 1992. In 1997, he moved to New York University where he served as professor of psychiatry and cell biology until his appointment as Paul C. Brucker, M.D., Professor of Neuroscience at Jefferson Medical College and Director of the Farber Institute for Neurosciences in 2001. In July 2007, he assumed his current post as Sinai Professor of Alzheimer’s Disease Research at the Mount Sinai School of Medicine. He is also a member of the Research Consortium of the Cure Alzheimer's Fund.[22]

In 2009, Gandy was featured with other prominent research scientists as one of GQ's "Rockstars of Science" [23] and featured in the documentary film I Remember Better When I Paint that examines the phenomenon of how the creative arts awaken pathways to emotional parts of the brain.[24]

gollark: +<markov 10
gollark: ++invite
gollark: \❌
gollark: I could rebrand heavserver as the official unofficial discord server for bees perhaps?
gollark: Apparently not.

References
  1. "Sam Gandy". Cure Alzheimer's Fund. Retrieved 2020-01-22.
  2. Kaiser, Jocelyn (30 August 2018). "The Alzheimer's gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease". Science. doi:10.1126/science.aav2455.
  3. "Medscape Neurology Scientific Advisory Board". www.medscape.com. Retrieved 2020-01-22.
  4. "Concussions May Leave Former NFL Players With Another Issue: Impotence". Consumer HealthDay. Retrieved 2020-01-22.
  5. "Alzheimer's Disease Treatment on MedicineNet.com". MedicineNet. Retrieved 2020-01-22.
  6. Australia, Dementia (2018-06-11). "Alzheimer's Australia National Conference 2017 - Speakers". www.dementia.org.au. Retrieved 2020-01-22.
  7. "South Australian Health and Medical Research Institute | 100&Change Solutions Bank". 100 and Change. Retrieved 2020-01-22.
  8. "GQ's Rock Stars of Science".
  9. "All My Fathers : Tickets". ALL MY FATHERS. Retrieved 2020-01-22.
  10. 5385915, Buxbaum, Joseph D.; Samuel E. Gandy & Paul Greengard, "United States Patent: 5385915 - Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation", issued January 31, 1995
  11. 5348963, Gandy, Samuel E.; Gregg L. Caporaso & Paul Greengard, "United States Patent: 5348963 - Method of screening for modulators of amyloid formation", issued September 20, 1994
  12. 5242932, Gandy, Samuel E.; Gregg L. Caporaso & Paul Greengard, "United States Patent: 5242932 - Treatment of amyloidosis associated with Alzheimer disease", issued September 7, 1993
  13. 4874694, Gandy, Samuel E. & Paul Greengard, "United States Patent: 4874694 - Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders", issued October 17, 1989
  14. Fossati, Valentina; Gandy, Samuel; Noggle, Scott. "Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease". Grantome.
  15. Ehrlich, Michelle; Gandy, Samuel; Haroutunian, Vahram; Iijima, Koichi; Noggle, Scott; Schadt, Eric; Zhang, Bin; Zhu, Jun. "Integrative Biology Approach to Complexity of Alzheimer's Disease". Grantome.
  16. "Integrated understanding of complex viral network biology in Alzheimer's Disease - Dimensions". app.dimensions.ai. Retrieved 2020-01-22.
  17. "SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD) - Dimensions". app.dimensions.ai. Retrieved 2020-01-22.
  18. "Alzheimer's Disease Research Center - Dimensions". app.dimensions.ai. Retrieved 2020-01-22.
  19. "Geoffrey Beene | Sam Gandy". Retrieved 2020-01-22.
  20. "Molecular Neurodegeneration". Molecular Neurodegeneration. Retrieved 2020-01-22.
  21. "Mount Sinai Hospital".
  22. "Cure Alzheimer's Fund".
  23. "MedScape Today".
  24. "Alzheimer's film: I Remember Better When I Paint, Paris Writer's News". 16 December 2009.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.